Portfolio
Overview

Watchlist
Overview


more

Portfolios Overview New Portfolio
Demo Portfolio
$75,350.00
Total Gain % 149.43%
Total Gain $25,350.00
Total Realised % 0.00%
Total Realised $0.00
Back
Watchlists Overview New Watchlist
Targets
33 Average Rating
Number of Companies 3
Date Created 04 Mar, 2015
Back
Portfolio Summary
Demo Portfolio
Market Value $75,350.00
Total Gain $25,350.00
(149.43%)
Value $42,315.00
Close Price (13 Apr) $141.05
Unrealised P/L (%) 149.40%
Unrealised P/L $25,350.00
Total $75,350.00
$25,350.00
Back
Back
Watchlist Summary
Targets
Short Name TGTS
Date Created 04 Mar, 2015
Current Price $64.95
Added Price $43.06
STRIDE Rating 36
Value Change (%) 50.85%
Current Price $33.88
Added Price $34.64
STRIDE Rating 25
Value Change (%) -2.19%
Current Price $26.74
Added Price $29.27
STRIDE Rating 35
Value Change (%) -8.63%
Total Buy0
Total Hold0
Total Sell3
Back
Back
Filter
Include in Feed
My Portfolios
My Watchlists
STRIDE Lists
Filter Feed By
STRIDE 3D VI
Activity
Upcoming
Warning
Back
Company FilterClear All
Filter by Company Descriptions
Filter by STRIDE Scores
Strength
to
Timing
to
Returns
to
Intrinsic Value
to
Dividends
to
Earnings Predictability
to
Rating
to
Back
Options
Add To Watchlist
Company Info (Sample)
Options
Add To Watchlist

Acasti Pharma Inc.

Acasti Pharma Inc.
Pharmaceuticals, Biotechnology and Life Sciences : Pharmaceuticals.
ACST on TSX Venture Exchange.
Price in Canadian Dollar, all financial data originally reported in Canadian Dollar.
Founded in 2002, the business is 15 years old.
The business last filed accounts on the 12 Jan, 2017.
Company website: www.acastipharma.com
Show Company Details
STRIDE Rating
00
Buy
Hold
Sell
Canada, Micro Cap
Market Capitalisation: $19.26M
Total Enterprise Value: Get a demo
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of various cardiometabolic disorders primarily abnormalities in blood lipids. The company offers Onemia, a medical food product for the dietary management of omega-3 phospholipids deficiency, and related abnormal lipid profiles and cardiometabolic disorders. It also develops CaPre, a prescription drug candidate for the prevention and treatment of cardiometabolic disorders, such as hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Read More
Price & Valuation Info
Price Quote on 13th Apr '17
$1.80 0.10(5.88%)
52 Week Range
1.47
4.03
Interactive STRIDE chart with history.
Only available to subscribers.
Get a demo now.
Performance
1 month 0.04 (2.27%)
year-to-date 0.05 (2.86%)
1 year 0.00 (0%)
Show More Valuation Info
Momentum
vs 52week high 45%
vs 50d SMA 106%
vs 200d SMA97%
STRIDE Valuations
Consider Buy Get a demo
Fair Value Get a demo
Consider Sell Get a demo
Price/Adj. Earnings Get a demo
Price/Adj FCF Get a demo
Price/Adj. TBV Get a demo
Forecast Growth Get a demo
Other Valuations
Price/Book Get a demo
Price/Tangible Book Get a demo
Price/Sales Get a demo
Price/Earnings Get a demo
Price/Free Cashflow Get a demo
EV/EBITDA Get a demo
Dividend Yield Get a demo
Volume
Ave. Vol. last 6 months
Hide Extra Info
Scores
S
Strength
T
Timing
R
Returns
I
Intrinsic Value
D
Dividends
E
Earnings Predictability
Other Metrics
Altman Z-Score (Bankruptcy)
Greenblatt Rank (Magic Formula)
Piotroski F-Score (Financial Health)
Beneish M-Score (Earnings Manipulation)
Financials Get a demo
To The Top
Company Options
Add To Watchlist
Watchlists:
Targets
Options
Price Alert Email:
Price to alert at:*
When to alert:*
Cancel
Save
Price Alerts Configured:
Back

Portfolio
Overview

Watchlist
Overview

Feed
Filter


more